SCHEMBL318214

SCHEMBL318214

CC#CCc1cc(N(CC(=O)N2CCOCC2)C(=O)C2CCC(C)CC2)c(C(=O)OC)s1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CYP2E1 P05181 1/20 0.59
▸ EPHX2 P34913 1/20 0.33
▸ ALDH1A1 P00352 4/20 0.32
▸ GLA P06280 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ POLB P06746 3/20 0.32
▸ MCOLN3 Q8TDD5 1/20 0.32
▸ APOBEC3G Q9HC16 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ NR1I2 O75469 2/20 0.31
▸ FKBP1A P62942 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ CNR1 P21554 1/20 0.31
▸ CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10265449 0.89 CYP2E1 (0.61) CYP2E1EPHX2ALDH1A1GLASMN1; SMN2
SCHEMBL10266124 0.88 CYP2E1 (0.58) CYP2E1EPHX2ALDH1A1GLASMN1; SMN2
SCHEMBL15123904 0.86 CYP2E1 (0.67) CYP2E1EPHX2ALDH1A1GLASMN1; SMN2
SCHEMBL10265040 0.86 CYP2E1 (0.67) CYP2E1EPHX2ALDH1A1GLASMN1; SMN2
SCHEMBL319216 0.85 CYP2E1 (0.64) CYP2E1EPHX2ALDH1A1GLASMN1; SMN2
SCHEMBL10265151 0.85 CYP2E1 (0.64) CYP2E1EPHX2ALDH1A1GLASMN1; SMN2
SCHEMBL10265779 0.85 CYP2E1 (0.57) CYP2E1EPHX2ALDH1A1GLASMN1; SMN2
SCHEMBL15130860 0.85 CYP2E1 (0.58) CYP2E1EPHX2ALDH1A1GLASMN1; SMN2
SCHEMBL10265447 0.85 CYP2E1 (0.58) CYP2E1EPHX2ALDH1A1GLASMN1; SMN2
SCHEMBL15123790 0.85 CYP2E1 (0.66) CYP2E1EPHX2ALDH1A1GLASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585447-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2013-05-01 — — EP disclosed
WO-2012006055-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-12 — — WO disclosed
Send feedback